AIM announces principal investigator for Ampligen, FluMist clinical study
AIM ImmunoTech (AIM) announced that Paul Goepfert, MD, of the University of Alabama-Birmingham, has agreed to act as the Principal Investigator ...
manilatimes2h
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic, stated: "I'm excited for the opportunity to follow-up on ...
Vietnam Investment Review on MSN3d
AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.
As global capital reassesses the investment value of innovative Chinese companies, the development of innovative vaccines in ...
Hosted on MSN1d
AIM Vaccine s mRNA RSV Vaccine Approved for U S Clinical Trials
Innovation and Global Expansion Attract Capital Reassessment AIM Vaccine Co., Ltd. (a joint stock company incorporated in the People's Republic of China with limited liability) (Stock Code: 6660.HK) ...
Hosted on MSN5d
AIM Vaccine Co., Ltd. Integrates AI for Strategic Upgrade
An update from AIM Vaccine Co., Ltd. Class H ( ($HK:6660) ) is now available. AIM Vaccine Co., Ltd. announced the strategic integration of ...
Yahoo Finance4d
AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside
HONG KONG, Feb. 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 23, 2025, announced that the company is fully ...
manilatimes1d
AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials
As global capital flows positively into the pharmaceutical sector, PRC vaccine leader AIM Vaccine (06660.HK) announced on February 26 that its self-developed mRNA RSV (Respiratory Syncytial Virus) ...
Yahoo Finance4d
AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside
HONG KONG, Feb. 24, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 23, 2025, announced that the company is fully deploying ...